Johnson & Johnson vs. Xeris Biopharma Holdings, Inc. Common Stock
JNJ
Johnson & Johnson
$269.47 -0.19%
VS XERSXeris Biopharma Holdings, Inc. Common Stock
$8.73 +6.52%
Johnson & Johnson (JNJ) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| JNJ | XERS | |
|---|---|---|
| Market Cap | $650.65 billion | $1.50 billion |
| Revenue (TTM) | $97.93 billion | $33.38 million |
| Net Income (TTM) | $21.04 billion | $-83,783,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | XERS | |
|---|---|---|
| P/E Ratio | 31.26 | — |
| Price / Book | 7.66 | 75.17 |
| Price / Sales | 6.64 | 44.79 |
JNJ leads on 2 of 2 valuation factors.
Profitability
| JNJ | XERS | |
|---|---|---|
| Net Margin | 21.48% | -251.01% |
| Return on Equity | 24.76% | -421.27% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| JNJ | XERS | |
|---|---|---|
| Dividend Yield | 1.99% | — |
| Payout Ratio | 62.18 | — |
JNJ and XERS split the dividend factors evenly.
Risk & Sentiment
| JNJ | XERS | |
|---|---|---|
| Short Interest | 0.67% | 0.10% |
XERS leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, XERS overview, XERS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.